Drug Detail

Information about NeoBOMB1

Generic Name	NeoBOMB1
IND	68Ga-NeoBOMB1
Brand Name (US)
Manufacturer	Advanced Accelerator Aplications
Drug Type	Antagonist bombesin analog
Delivery	Intravenous
Approval Status	Phase 1
Indications
Overall Strategy	GIST Tumor Based
Strategy	Radio labeled tracer for GRPR expressing malignancies
Drug Category	SDH-directed

Radiotracer for imaging and therapy of GRPR-expressing tumors.

Gastrin Releasing Peptide Receptors (GRPR)

177Lu-NEOBOMB1 and 68Ga-NEOBOM1. NeoBOMB1 is a unique new generation antagonist bombesin analogue targeting GRPR-expressing malignancies. Our plan is to radiolabel NeoBOMB1 to develop a theragnostic pair: 177Lu-NeoBOMB1 for treatment and a 68Ga-NeoBOMB1 for diagnosis. AAA has signed an exclusive license agreement with Erasmus University Medical Center (UMC) and Demokritos National Center for Scientific Research to develop NeoBOMB1. AAA is currently planning three clinical studies in different indications including gastrointestinal stromal tumors, prostate cancer and breast cancer.